Contact us
Please fill out the details below and we will get back to you shortly.
Thank you!
We will be contacting you soon..
Close
We will be contacting you soon..
Oops! Something went wrong while submitting the form.
October 2024 - Portal presented the poster "Addressing the Challenges of Highly Viscous Formulations Using a Needle-Free Technology" at the The PDA Universe of Pre-Filled Syringes and Injection Devices Conference in Arizona.
October 2024 - Portal recently shared its latest research at The PDA Universe of Pre-Filled Syringes and Injection Devices Conference in Arizona. The poster "Addressing the Challenges of Highly Viscous Formulations
Using a Needle-Free Technology" showed ex-vivo testing results which demonstrated PRIME Needle-Free injector can eject consistently and faster than a needle and syringe, while depositing the injectate at a similar depth in the subcutaneous space.
The ability for PRIME NF to eject high viscosity fluids consistently and rapidly could open the doors for new therapies as well as increase patient access to a more agreeable method of drug delivery. Having a needle-free system not only quells the common fear of needles but also boasts faster and more reliable injection times than a mechanical autoinjector. The findings of this study hint at the prospect of pushing beyond the constraints imposed by current needle-based injection devices.
November 2024, Cambridge, MA – Seasoned drug delivery executive, Steven Kaufman, to join Portal Instruments as their Chief Commercial Officer. Prior to joining Portal Instruments in November 2024, Steven held executive positions at Stevanato Group, Bespak and SHL Medical.
December 21, 2021 - In the consumer tech world, iterations happen very fast, though most inventions are not ‘one and done’ masterpieces: the Dyson cyclone vacuum cleaner made 5,127 prototypes. In the medical device world, development takes longer.
May 10, 2022 - Portal Instruments has been featured in Fierce Pharma. "Gerresheimer invests in Portal's needle-free drug delivery, teeing Takeda partner up to advance tech", showcases Gerresheimer's agreement with Portal to support the development of the needle-free drug delivery platform.
Please fill out the details below and we will get back to you shortly.